Could the emerging artificial intelligence platforms Saige-Dx and Quantib Prostate 2.0 improve cancer detection with mammography and prostate MRI?
RadNet has garnered 510(k) clearances from the Food and Drug Administration (FDA) for the artificial intelligence (AI)-enabled algorithms Saige-Dx™, which aids in detecting suspicious findings on mammograms, and Quantib® Prostate 2.0, which may bolster reporting of prostate magnetic resonance imaging (MRI) exams.
Saige-Dx reportedly enhances the detection of suspicious lesions on mammograms and reduces recalls, according to RadNet. Built on advanced deep learning algorithms, Saige-Dx decreased false positive rates and improved the ability of 18 radiologists to detect cancer in a study that preceded the FDA 510(k) clearance, noted DeepHealth, a subsidiary of RadNet.
Quantib Prostate 2.0 provides automated segmentation of prostate zones and glands as well as lesion localization on the PI-RADS sector map, according to RadNet.
The company noted that the software program enhances the quality and speed of reporting with prostate MRI exams. RadNet said other benefits of Quantib Prostate 2.0 include PSA density calculation, PI-RADS scoring support and one-click segmentation of possible lesions.
“Artificial intelligence will have a transforming impact on radiology and cancer care, and we are committed to delivering those advances to patients and health-care providers,” noted Howard Berger, the president and chief executive officer of RadNet. “ … We believe that these AI tools will play an important role in the early detection and diagnosis of cancer, resulting in improved survival rates and better patient outcomes.”
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.